Skip to content

Study · Animal study (in vivo) · rat · 2019

4 results

Therapy of the rat hemorrhagic cystitis induced by cyclophosphamide. Stable gastric pentadecapeptide BPC 157, L-arginine, L-NAME.

Sucic M, Luetic K, Jandric I, Drmic D, Sever AZ, Vuletic LB, Halle ZB, Strinic D, Kokot A, Seiwerth RS, Zoricic I, Blagaic AB, Seiwerth S, Sikiric P

European journal of pharmacology8 Aug 2019Cited by 39 (Europe PMC)

PMID31401154 (opens in a new tab)DOI10.1016/j.ejphar.2019.172593 (opens in a new tab)PepBankPUB-31401154
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with cyclophosphamide-induced hemorrhagic cystitis, BPC‑157 given after cyclophosphamide, in either dose or regimen, markedly attenuated the gross and microscopic cyclophosphamide lesions.

    In plain wordsIn rats with bladder damage from cyclophosphamide, BPC‑157 clearly reduced the bladder lesions seen by eye and under the microscope.

    Peptide
    BPC-157
    Outcome
    DecreaseCyclophosphamide-induced hemorrhagic cystitis lesions (gross and microscopic)
    Study

    Ratsn: not reported in source

    Cyclophosphamide-induced hemorrhagic cystitis (100 mg/kg/day intraperitoneally for three days)
    Outcome group
    Organ injury · Kidney and urinary
    Studied dose
    10 μg/kg/day, 10 ng/kg/day · Intraperitoneal or peroral (in drinking water)As given in this study (Rats).

    Source sentences

    Summary
    BPC 157 administration after cyclophosphamide, given in either dose or in either regimen markedly attenuated all cyclophosphamide lesions, grossly, microscopically.
    2 context sentences
    Summary · context
    We focused on the cyclophosphamide-induced hemorrhagic cystitis (100 mg/kg/day intraperitoneally throughout three days)
    Summary · context
    BPC 157 (10 μg/kg/day, 10 ng/kg/day, intraperitoneally or perorally, in drinking water).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats with cyclophosphamide-induced hemorrhagic cystitis, BPC‑157 consistently attenuated the increase of bladder wet weight.

    In plain wordsIn rats with bladder damage from cyclophosphamide, BPC‑157 reduced the rise in bladder weight.

    Peptide
    BPC-157
    Outcome
    DecreaseBladder wet weight
    Study

    Ratsn: not reported in source

    Cyclophosphamide-induced hemorrhagic cystitis (100 mg/kg/day intraperitoneally for three days)
    Outcome group
    Organ injury · Kidney and urinary
    Studied dose
    10 μg/kg/day, 10 ng/kg/day · Intraperitoneal or peroral (in drinking water)As given in this study (Rats).

    Source sentences

    Summary
    The increase of the bladder wet weight was consistently attenuated.
    2 context sentences
    Summary · context
    We focused on the cyclophosphamide-induced hemorrhagic cystitis (100 mg/kg/day intraperitoneally throughout three days)
    Summary · context
    BPC 157 (10 μg/kg/day, 10 ng/kg/day, intraperitoneally or perorally, in drinking water).
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats with cyclophosphamide-induced hemorrhagic cystitis, BPC‑157 reversed the increased leak point pressure to the values noted in normal rats.

    In plain wordsIn rats with bladder damage from cyclophosphamide, BPC‑157 brought the raised leak point pressure back to normal rat values.

    Peptide
    BPC-157
    Outcome
    DecreaseLeak point pressure
    Study

    Ratsn: not reported in source

    Cyclophosphamide-induced hemorrhagic cystitis (100 mg/kg/day intraperitoneally for three days)
    Outcome group
    Urinary continence and bladder function · Kidney and urinary
    Studied dose
    10 μg/kg/day, 10 ng/kg/day · Intraperitoneal or peroral (in drinking water)As given in this study (Rats).

    Source sentences

    Summary
    Functionally, increased leak point pressure was reversed to the values noted in normal rats.
    2 context sentences
    Summary · context
    We focused on the cyclophosphamide-induced hemorrhagic cystitis (100 mg/kg/day intraperitoneally throughout three days)
    Summary · context
    BPC 157 (10 μg/kg/day, 10 ng/kg/day, intraperitoneally or perorally, in drinking water).
  4. 04AnimalAnimal study (in vivo)Mechanism

    In rats with cyclophosphamide-induced hemorrhagic cystitis, similar findings were noted when BPC‑157 was given together with L-NAME or L-arginine, alone or combined.

    In plain wordsIn rats with bladder damage from cyclophosphamide, BPC‑157 had similar effects when given with L-NAME or L-arginine.

    Peptide
    BPC-157
    Outcome
    Direction not reportedBPC 157 effect together with L-NAME or L-arginine
    Study

    Ratsn: not reported in source

    Cyclophosphamide-induced hemorrhagic cystitis (100 mg/kg/day intraperitoneally for three days)
    Outcome group
    Organ injury · Kidney and urinary
    Studied dose
    10 μg/kg/day, 10 ng/kg/day · Intraperitoneal or peroral (in drinking water)As given in this study (Rats).

    Source sentences

    Summary
    The similar findings were noted in rats that received BPC 157 together with L-NAME or L-arginine, given alone or combined.
    2 context sentences
    Summary · context
    We focused on the cyclophosphamide-induced hemorrhagic cystitis (100 mg/kg/day intraperitoneally throughout three days)
    Summary · context
    BPC 157 (10 μg/kg/day, 10 ng/kg/day, intraperitoneally or perorally, in drinking water).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 12:39 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.